Adar Hoffman
About Adar Hoffman
Adar Hoffman is a Regulatory Manager at Bristol Myers Squibb with over a decade of experience in regulatory affairs within the pharmaceutical industry.
Current Position
Adar Hoffman is currently working as a Regulatory Manager at Bristol Myers Squibb. In this role, they oversee the compliance of pharmaceutical products with regulations and standards to ensure safety and efficacy. Their ongoing responsibilities include maintaining updated knowledge of regulatory requirements and guiding product development and marketing to meet those standards.
Previous Experience at Novo Nordisk
Before joining Bristol Myers Squibb, Adar Hoffman held a position at Novo Nordisk as a Pharmaceutical Sales representative from 2019 to 2021. During this period, they developed sales strategies, engaged with healthcare professionals, and promoted Novo Nordisk's portfolio of pharmaceutical products. This experience enhanced their understanding of the pharmaceutical market and customer needs.
Role at Takeda
From 2016 to 2019, Adar Hoffman served as a Regulatory Affairs Specialist at Takeda. Here, they honed their skills in managing regulatory submissions, ensuring compliance with regulatory agencies, and maintaining documentation for pharmaceutical products. This role built upon their foundational knowledge of regulatory affairs and provided significant industry insights.
Early Career at Neopharm Group
Adar Hoffman began their career in regulatory affairs at Neopharm Group, where they spent six years from 2010 to 2016 as a Regulatory Affairs Specialist. Their responsibilities included preparing and submitting regulatory documents, coordinating with regulatory authorities, and ensuring that product information complied with relevant regulations. This position laid the groundwork for their expertise in regulatory affairs.
Educational Background
Adar Hoffman pursued higher education at Tel Aviv University, where they earned both a Bachelor's and a Master's degree. They completed a Bachelor of Science in Chemistry and Biology from 2005 to 2009, providing a robust scientific foundation. Subsequently, they attended the Coller School of Management at the same university, achieving a Master of Business Administration (MBA) from 2016 to 2018. This combination of scientific and business education underpins their proficiency in regulatory affairs.